Helmedix Pty, a biotech spin out using technology first developed at the University of Technology, Sydney’s biotech research unit ithree institute, has launched with a $1.29m investment from Australia’s Medical Research Commercialisation Fund (MRCF).

The Australia-based spin-out will use the funding to develop therapeutic peptide drugs for preventing and treating immunological diseases which currently affect millions worldwide.

UTS’ research commercialisation partner UniQuest negotiated the licensing deal.

“Bringing together the MRCF and the ithree institute to launch Helmedix is an excellent…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?